whole-genome microarray-based transcriptome profiling using (Illumina Inc)
Structured Review
Whole Genome Microarray Based Transcriptome Profiling Using, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/whole-transcriptome+microarray+profiling/whole+genome+microarray+based+transcriptome+profiling/pmc08945692-1-61-61
Average 90 stars, based on 1 article reviews
Images
Related Articles
other:Article Title: ePoster Session 1 Article Snippet: Introduction: Late Onset Multiple Sclerosis (LOMS) is defined as presentation of the first clinical symptoms in patients >50, and its prevalence is described between 4%-9.6% in different studies.. LOMS is usually associated with a faster progression to disability as compared to young-adult multiple sclerosis (MS).. The course is often progressive and the main form of presentation is pyramidal involvement. Article Title: Flash Posters Article Snippet: We are performing a whole-genome microarray-based transcriptome profiling using Article Title: Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination Article Snippet: Sorosina et al. Observational Clinical Study [ ] , 2016 2018 , A total of 93 nabiximols-treated MS patients across Italy were enrolled in an observational study. Whole blood was collected at baseline, 4 weeks (n = 93), and 14 weeks (n = 33, n = 19 responders and n = 14 non-responders) and analyzed by whole-genome microarray-based transcriptome profiling using |
Table S1 ). Enrichment of cytokine-responsive transcriptional signatures was evaluated in the 